Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates

被引：15
|
作者：
Muratore, Maurizio [1 ]
Quarta, Eugenio [1 ]
Grimaldi, Antonella [1 ]
Calcagnile, Fabio [1 ]
Quarta, Laura [1 ]
机构：
[1] Hosp Galateo, Dept Rheumatol, I-73016 San Cesario Di Lecce, Italy
来源：
DRUG DESIGN DEVELOPMENT AND THERAPY | 2011年 / 5卷
关键词：
clodronate; bisphosphonates; osteoporosis; bone turnover; menopause; tolerability; BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; DOUBLE-BLIND; RISK-FACTORS; INTRAVENOUS CLODRONATE; INFLAMMATORY ACTIONS; VERTEBRAL FRACTURES; HIP FRACTURE; OPEN-LABEL; WOMEN;
D O I：
10.2147/DDDT.S12139
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Bisphosphonates have a long history in the treatment of osteoporosis and bone-related disease. This review focuses on the use of a specific nonaminobisphosphonate, clodronate, which appears to be much better tolerated than other bisphosphonates and free of high-risk contraindications. Specifically, this paper reviews its use in the prevention of osteoporosis in postmenopausal women, taking into account its tolerability profile and recent safety issues arising regarding the use of bisphosphonates.
引用
收藏
页码：445 / 454
页数：10
相关论文
共 50 条
  • [1] Treatment of osteoporosis in women intolerant of oral bisphosphonates
    Aspray, Terry J.
    Francis, Roger M.
    MATURITAS, 2012, 71 (01) : 76 - 78
  • [2] Clinical Strategies to Address Patients' Concerns in Osteoporosis Management with Bisphosphonates
    Cole, Raymond E.
    POSTGRADUATE MEDICINE, 2011, 123 (02) : 131 - 144
  • [3] Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice
    Thomas, T.
    Horlait, S.
    Ringe, J. D.
    Abelson, A.
    Gold, D. T.
    Atlan, P.
    Lange, J. L.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 263 - 269
  • [4] The oral health status of patients on oral bisphosphonates for osteoporosis
    Kunchur, R.
    Goss, A. N.
    AUSTRALIAN DENTAL JOURNAL, 2008, 53 (04) : 354 - 357
  • [5] Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis
    Naylor, K. E.
    Mccloskey, E., V
    Jacques, R. M.
    Peel, N. F. A.
    Paggiosi, M. A.
    Gossiel, F.
    Walsh, J. S.
    Eastell, R.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 (04) : 917 - 922
  • [6] The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
    Hiligsmann, Mickael
    Rabenda, Veronique
    Bruyere, Olivier
    Reginster, Jean-Yves
    HEALTH POLICY, 2010, 96 (02) : 170 - 177
  • [7] Clinical Efficacy of Bisphosphonates in Treating Osteoporosis in Diabetes Patients: A Meta-Analysis
    Yang, Yuan-Xun
    Jin, Yan
    HORMONE AND METABOLIC RESEARCH, 2024, 56 (11) : 795 - 806
  • [8] Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
    Yuan, Chuanjian
    Liang, Yanchen
    Zhu, Kai
    Xie, Wenpeng
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2023, 18 (01)
  • [9] Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis
    K.E. Naylor
    E.V. McCloskey
    R.M. Jacques
    N.F.A. Peel
    M.A. Paggiosi
    F. Gossiel
    J.S. Walsh
    R. Eastell
    Osteoporosis International, 2019, 30 : 917 - 922
  • [10] Bisphosphonates in the management of postmenopausal osteoporosis - optimizing efficacy in clinical practice
    Bock, Oliver
    Felsenberg, Dieter
    CLINICAL INTERVENTIONS IN AGING, 2008, 3 (02) : 279 - 297
12345